In the FLOW trial, semaglutide reduced risk of clinically important kidney outcomes and reduced cardiovascular death in people with type 2 diabetes and chronic kidney disease.
normativepending
Speaker
Dr. Amin DadgarEvidence Quote
“In people with type 2 diabetes and chronic kidney disease, the FLOW trial showed semaglutide reduced risk of clinically important kidney outcomes and reduced cardiovascular death.”
Created: 8/12/2026, 6:40:36 PM
Your notes
Loading notes...